Skip to main content
Top
Published in: BMC Cancer 1/2020

01-12-2020 | Radiotherapy | Research article

A prognostic nomogram for the cancer-specific survival of patients with upper-tract urothelial carcinoma based on the Surveillance, Epidemiology, and End Results Database

Authors: Chengzhuo Li, Jin Yang, Fengshuo Xu, Didi Han, Shuai Zheng, Rahel Elishilia Kaaya, Shengpeng Wang, Jun Lyu

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

The aim of this study was to establish a comprehensive nomogram for the cancer-specific survival (CSS) of patients with upper-tract urothelial carcinoma (UTUC) and compare it with the traditional American Joint Committee on Cancer (AJCC) staging system in order to determine its reliability.

Methods

This study analyzed 9505 patients with UTUC in the Surveillance, Epidemiology, and End Results (SEER) database. R software was used to randomly divided the patients in a 7-to-3 ratio to form a training cohort (n = 6653) and a validation cohort (n = 2852). Multivariable Cox regression was used to identify predictive variables. The new survival model was compared with the AJCC prognosis model using the concordance index (C-index), the area under the time-dependent receiver operating characteristics curve (AUC), the net reclassification improvement (NRI), the integrated discrimination improvement (IDI), calibration plotting, and decision-curve analysis (DCA).

Results

We have established a nomogram for determining the 3-, 5-, and 8-year CSS probabilities of UTUC patients. The nomogram indicates that the AJCC stage has the greatest influence on CSS in UTUC, followed by the age at diagnosis, surgery status, tumor size, radiotherapy status, histological grade, marital status, chemotherapy status, race, and finally sex. The C-index was higher for the nomogram than the AJCC staging system in both the training cohort (0.785 versus 0.747) and the validation cohort (0.779 versus 0.739). Calibration plotting demonstrated that the model has good calibration ability. The AUC, NRI, IDI, and DCA of the nomogram showed that it performs better than the AJCC staging system alone.

Conclusions

This study is the first to establish a comprehensive UTUC nomogram based on the SEER database and evaluate it using a series of indicators. Our novel nomogram can help clinical staff to predict the 3-, 5-, and 8-year CSS probabilities of UTUC patients more accurately than using the AJCC staging system.
Literature
1.
go back to reference Roupret M, Babjuk M, Comperat E, et al. European Association of Urology guidelines on upper urinary tract Urothelial carcinoma: 2017 update. Eur Urol. 2018;73(1):111–22.CrossRef Roupret M, Babjuk M, Comperat E, et al. European Association of Urology guidelines on upper urinary tract Urothelial carcinoma: 2017 update. Eur Urol. 2018;73(1):111–22.CrossRef
2.
go back to reference Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int. 2011;107(7):1059–64.CrossRef Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int. 2011;107(7):1059–64.CrossRef
3.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.CrossRef
4.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.CrossRef
5.
go back to reference Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRef Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30.CrossRef
6.
go back to reference Seaman EK, Slawin KM, Benson MC. Treatment options for upper tract transitional-cell carcinoma. Urol Clin North Am. 1993;20(2):349–54.PubMed Seaman EK, Slawin KM, Benson MC. Treatment options for upper tract transitional-cell carcinoma. Urol Clin North Am. 1993;20(2):349–54.PubMed
7.
go back to reference Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and Neoadjuvant chemotherapy for upper tract Urothelial carcinoma. Eur Urol. 2014;66(3):529–41.CrossRef Leow JJ, Martin-Doyle W, Fay AP, Choueiri TK, Chang SL, Bellmunt J. A systematic review and meta-analysis of adjuvant and Neoadjuvant chemotherapy for upper tract Urothelial carcinoma. Eur Urol. 2014;66(3):529–41.CrossRef
8.
go back to reference Krogh J, Kvist E, Rye B. Transitional cell carcinoma of the upper urinary tract: prognostic variables and post-operative recurrences. Br J Urol. 1991;67(1):32–6. Krogh J, Kvist E, Rye B. Transitional cell carcinoma of the upper urinary tract: prognostic variables and post-operative recurrences. Br J Urol. 1991;67(1):32–6.
9.
go back to reference Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93‐9. Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93‐9.
10.
go back to reference Novara G, De Marco V, Gottardo F, et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer. 2007;110(8):1715–22.CrossRef Novara G, De Marco V, Gottardo F, et al. Independent predictors of cancer-specific survival in transitional cell carcinoma of the upper urinary tract: multi-institutional dataset from 3 European centers. Cancer. 2007;110(8):1715–22.CrossRef
11.
go back to reference Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical Nephroureterectomy for upper tract Urothelial carcinoma. Eur Urol. 2012;61(4):818–25.CrossRef Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical Nephroureterectomy for upper tract Urothelial carcinoma. Eur Urol. 2012;61(4):818–25.CrossRef
12.
go back to reference Xylinas E, Kluth L, Passoni N, et al. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol. 2014;65(3):650–8.CrossRef Xylinas E, Kluth L, Passoni N, et al. Prediction of intravesical recurrence after radical nephroureterectomy: development of a clinical decision-making tool. Eur Urol. 2014;65(3):650–8.CrossRef
13.
go back to reference Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a Nomogram for Cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.CrossRef Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a Nomogram for Cancer prognosis. J Clin Oncol. 2008;26(8):1364–70.CrossRef
15.
go back to reference Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1975–2016), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission. Surveillance, Epidemiology, and End Results (SEER) Program (www.​seer.​cancer.​gov) Research Data (1975–2016), National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission.
16.
go back to reference Yang J, Liu QQ, Geng H, Tian GX, Zeng XT, Lyu J. SEER database application and data extraction methods and processes. Chin J Evid Based Cardiovasc Med. 2018;10(07):781–4. Yang J, Liu QQ, Geng H, Tian GX, Zeng XT, Lyu J. SEER database application and data extraction methods and processes. Chin J Evid Based Cardiovasc Med. 2018;10(07):781–4.
17.
go back to reference Simone G, Papalia R, Loreto A, Leonardo C, Sentinelli S, Gallucci M. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma. BJU Int. 2009;103(8):1052–7.CrossRef Simone G, Papalia R, Loreto A, Leonardo C, Sentinelli S, Gallucci M. Independent prognostic value of tumour diameter and tumour necrosis in upper urinary tract urothelial carcinoma. BJU Int. 2009;103(8):1052–7.CrossRef
18.
go back to reference Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index. Stat Med. 2014;33(19):3405–14.CrossRef Hilden J, Gerds TA. A note on the evaluation of novel biomarkers: do not rely on integrated discrimination improvement and net reclassification index. Stat Med. 2014;33(19):3405–14.CrossRef
19.
go back to reference Parikh CR, Coca SG, Thiessen-Philbrook H, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748–57.CrossRef Parikh CR, Coca SG, Thiessen-Philbrook H, et al. Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol. 2011;22(9):1748–57.CrossRef
20.
go back to reference Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671–80.CrossRef Callegaro D, Miceli R, Bonvalot S, et al. Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016;17(5):671–80.CrossRef
21.
go back to reference Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565–74.CrossRef Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26(6):565–74.CrossRef
22.
go back to reference Stewart GD, Bariol SV, Grigor KM, Tolley DA, McNeill SA. A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int. 2005;95(6):791–3.CrossRef Stewart GD, Bariol SV, Grigor KM, Tolley DA, McNeill SA. A comparison of the pathology of transitional cell carcinoma of the bladder and upper urinary tract. BJU Int. 2005;95(6):791–3.CrossRef
23.
go back to reference Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80.CrossRef Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173–80.CrossRef
24.
go back to reference Eylert MF, Hounsome L, Verne J, Bahl A, Jefferies ER, Persad RA. Prognosis is deteriorating for upper tract urothelial cancer: data for England 1985–2010. BJU Int. 2013;112(2):e107–13.CrossRef Eylert MF, Hounsome L, Verne J, Bahl A, Jefferies ER, Persad RA. Prognosis is deteriorating for upper tract urothelial cancer: data for England 1985–2010. BJU Int. 2013;112(2):e107–13.CrossRef
25.
go back to reference Lughezzani G, Jeldres C, Isbarn H, et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer. 2009;45(18):3291–7.CrossRef Lughezzani G, Jeldres C, Isbarn H, et al. Nephroureterectomy and segmental ureterectomy in the treatment of invasive upper tract urothelial carcinoma: a population-based study of 2299 patients. Eur J Cancer. 2009;45(18):3291–7.CrossRef
26.
go back to reference Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagn Progn Res. 2019;3:18.CrossRef Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagn Progn Res. 2019;3:18.CrossRef
27.
go back to reference Fernandez MI, Shariat SF, Margulis V, et al. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. Urology. 2009;73(1):142–6.CrossRef Fernandez MI, Shariat SF, Margulis V, et al. Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. Urology. 2009;73(1):142–6.CrossRef
28.
go back to reference Aizer AA, Chen M-H, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869–76.CrossRef Aizer AA, Chen M-H, McCarthy EP, Mendu ML, Koo S, Wilhite TJ, Graham PL, Choueiri TK, Hoffman KE, Martin NE, et al. Marital status and survival in patients with cancer. J Clin Oncol. 2013;31(31):3869–76.CrossRef
29.
go back to reference Cohen SD, Sharma T, Acquaviva K, Peterson RA, Patel SS, Kimmel PL. Social support and chronic kidney disease: an update. Adv Chronic Kidney Dis. 2007;14(4):335–44.CrossRef Cohen SD, Sharma T, Acquaviva K, Peterson RA, Patel SS, Kimmel PL. Social support and chronic kidney disease: an update. Adv Chronic Kidney Dis. 2007;14(4):335–44.CrossRef
30.
go back to reference Buja A, Lago L, Lago S, Vinelli A, Zanardo C, Baldo V. Marital status and stage of cancer at diagnosis: A systematic review. Eur J Cancer Care. 2018;27(1):e12755.CrossRef Buja A, Lago L, Lago S, Vinelli A, Zanardo C, Baldo V. Marital status and stage of cancer at diagnosis: A systematic review. Eur J Cancer Care. 2018;27(1):e12755.CrossRef
31.
go back to reference Leow JJ, Orsola A, Chang SL, Bellmunt J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. 2015;41(4):310–9.CrossRef Leow JJ, Orsola A, Chang SL, Bellmunt J. A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer Treat Rev. 2015;41(4):310–9.CrossRef
32.
go back to reference Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the upper tract Urothelial carcinoma collaboration. Cancer. 2009;115(6):1224–33.CrossRef Margulis V, Shariat SF, Matin SF, et al. Outcomes of radical nephroureterectomy: a series from the upper tract Urothelial carcinoma collaboration. Cancer. 2009;115(6):1224–33.CrossRef
33.
go back to reference Raman JD, Ng CK, Scherr DS, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol. 2010;57(6):1072–9.CrossRef Raman JD, Ng CK, Scherr DS, et al. Impact of tumor location on prognosis for patients with upper tract urothelial carcinoma managed by radical nephroureterectomy. Eur Urol. 2010;57(6):1072–9.CrossRef
34.
go back to reference Iki M, Fujita Y, Tamaki J, et al. Trabecular bone score may improve FRAX(R) prediction accuracy for major osteoporotic fractures in elderly Japanese men: the Fujiwara-kyo osteoporosis risk in men (FORMEN) cohort study. Osteoporos Int. 2015;26(6):1841–8.CrossRef Iki M, Fujita Y, Tamaki J, et al. Trabecular bone score may improve FRAX(R) prediction accuracy for major osteoporotic fractures in elderly Japanese men: the Fujiwara-kyo osteoporosis risk in men (FORMEN) cohort study. Osteoporos Int. 2015;26(6):1841–8.CrossRef
35.
go back to reference Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med. 2011;30(1):22–38.CrossRef Chambless LE, Cummiskey CP, Cui G. Several methods to assess improvement in risk prediction models: extension to survival analysis. Stat Med. 2011;30(1):22–38.CrossRef
36.
go back to reference Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128–38.CrossRef Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128–38.CrossRef
Metadata
Title
A prognostic nomogram for the cancer-specific survival of patients with upper-tract urothelial carcinoma based on the Surveillance, Epidemiology, and End Results Database
Authors
Chengzhuo Li
Jin Yang
Fengshuo Xu
Didi Han
Shuai Zheng
Rahel Elishilia Kaaya
Shengpeng Wang
Jun Lyu
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07019-5

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine